secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2022-11-29T23:59:59+00:00
Accession:  0000950170-22-025765
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology appoints Scott Garland to Board of Directors effective Nov 28, 2022
--------------------------------------------------------------------------------

- Appointed Scott Garland to Board of Directors effective November 28, 2022; Board size increased from 7 to 8.
- Garland is CEO of PACT Pharma, former CEO of Portola Pharmaceuticals, with 30+ years in biopharma.
- Automatic grant of initial stock options for 24,009 shares, vesting monthly over three years.
- Garland also serves on boards of Calithera Biosciences and Day One Biopharmaceuticals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017022025765/0000950170-22-025765-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017022025765/alxo-20221128.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-025765

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer